As a result, it is highly probable that Rab25 mediates erlotinib resistance by mediating the recycling of β1 integrin to the cytoplasmic membrane, which leads to AKT phosphorylation and subsequent downstream signalling to promote tumour cell proliferation. Here, AKT1 is linked to neoplasm.